Home > News & Media > News
Communication starts here.
2015.04
TWi Announces Settlement with Takeda on Dexilant® Litigation
2015.04
TWi Pharmaceuticals USA Announces the Receipt of State Sales Licenses from All 50 States in the U.S.
2015.03
TWi Pharmaceuticals announces the first shipment of its generic product in the U.S. market.
2015.03
TWi Biotechnology Receives Rare Disease Drug Designation for its Drug Candidate AC-203 in Taiwan.
2015.03
TWi Pharmaceuticals announces that its Board has appointed Ms. Tina Guilder as the President & CEO and Ms. Eva Ho as CFO to enhance the strategic move to commercialize its products in the U.S. market.
2015.02
TWi Pharmaceuticals announces that it will sell its products in the U.S. market, originally planned to be sold by Teva, through its wholly-owned subsidiary, TWi Pharmaceuticals USA
2015.01
TWi Confirms Patent Challenge Relating to Oxtellar XR®, Oxcarbazepine ER Tablet
2014.12
TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China
2014.12
TWi Biotechnology receives approval of protocol for its drug AC-201 Controlled-Release Tablet, Phase II clinical trial in both the United States and Taiwan
2014.10
TWi Pharmaceuticals Receives US FDA Approval on Generic Donepezil Hydrochloride Tablets USP, 23 mg, its fifth ANDA from US FDA

 

Pages:1 - 2 - 3 - 4 - 5« Pre · Next »